Dave Young
MD Student with Scholarly Concentration in Community Health / Global Health, expected graduation Spring 2030
All Publications
-
Pupillary Diameter and Image Count in Telemedicine ROP Parameter Classification.
Ophthalmology. Retina
2026
Abstract
We examined whether pupillary diameter (PD) and image count (IC) are associated with detection of ICROP3 parameters in 10,503 eye-sessions from 1,131 infants in the SUNDROP telemedicine program. PD was graded on the anterior segment image as Large (8 mm), Medium (6-7 mm), or Small (≤5 mm). In mixed-effects models adjusted for gestational age, birth weight, and postmenstrual age, smaller PD was associated with Plus disease (Small vs Large: OR 2.41, 95% CI 1.36-4.29) and P-score, and each additional image with higher graded Stage, Plus, and P-score. Among Small pupils, additional images did not improve detection of any parameter.
View details for DOI 10.1016/j.oret.2026.10.009
View details for PubMedID 42951111
-
tRNA dosage regulates lineage dependency and resistance in prostate cancer.
Nature
2026
Abstract
Lineage plasticity underlies therapeutic resistance in cancer1,2, yet the translational mechanisms that enable this phenotypic flexibility remain largely unknown. Here using prostate cancer as a model of lineage dependence, we performed unbiased small RNA sequencing and identified tRNA1Arg(UCU) as a regulator of lineage transitions and therapy resistance. tRNA1Arg(UCU) is capable of reprogramming lineage dependence, which can be tuned to restore sensitivity to therapies that target the androgen receptor. We identify TARDBP and ZSCAN29 as DNA-binding proteins that directly engage the genomic locus of tRNA1Arg(UCU) to regulate its expression, a result that highlights the importance of non-canonical tRNA-specific gene regulation. Mechanistically, tRNA1Arg(UCU) controls a translational program centred on SWI/SNF chromatin remodellers, which is necessary to maintain lineage fidelity. In patients, tRNA1Arg(UCU) is downregulated in neuroendocrine prostate cancer and its loss is associated with accelerated metastasis and poor survival. These findings uncover a previously unrecognized tRNA-specific regulatory axis that links codon biology to lineage dependence and therapy resistance in prostate cancer.
View details for DOI 10.1038/s41586-026-11153-8
View details for PubMedID 42844465
View details for PubMedCentralID 7397755
-
Worksite Vision Screening for Farmworkers: A California Bay Area Pilot Study.
Clinical ophthalmology (Auckland, N.Z.)
2026; 20: 640548
Abstract
Farmworkers face high risk of ocular disease, yet substantial barriers to vision care. We conducted a pilot implementation of a worksite vision screening at a commercial farm, characterizing participant demographics, ocular pathology, vision-related quality of life, and barriers to care.A one-time vision screening was conducted at a farm in the California Bay Area. Participants completed a demographic intake, the Vision Quality of Life (VisQoL) Index, and a survey on self-reported barriers to care. All received an eye exam, including visual acuity, intraocular pressure, slit lamp, and dilated fundus evaluation. Glasses were distributed on-site. Patients with pathology requiring follow-up were referred to in-network providers.Eighty-five farmworkers were screened (mean age 47.1 years; 71.8% male). Best presenting visual acuity was 20/40 or worse in 20.0% of participants. The most common diagnoses were refractive error (81.2%, including presbyopia and astigmatism), cataracts (22.4%), dry eye/meibomian gland dysfunction (20.0%), and glaucoma suspect (16.5%). Nineteen participants (22.4%) were referred for further care. Of ten participants with self-reported diabetes, three had diabetic retinopathy. The most common barriers were cost (20.0%), competing work or caregiving obligations (15.3%), and appointment difficulty (11.8%).This worksite screening reached over one-third of the workforce in a single day, provided same-day refractive correction to 62.4% of participants, and identified previously undetected ocular pathology. It may represent a scalable approach for delivering preventive eye care to farmworker communities with limited access to clinic-based services, although feasibility and linkage to follow-up care were not assessed.
View details for DOI 10.2147/OPTH.S640548
View details for PubMedID 43036508
View details for PubMedCentralID PMC13770380
-
Lung transplant perspectives in the era of elexacaftor/tezacaftor/ivacaftor (ETI): Navigating clinical uncertainty and ETI limbo among people with cystic fibrosis, a qualitative analysis.
Heart & lung : the journal of critical care
2026; 80: 102969
Abstract
Improved health among people with cystic fibrosis (PwCF) taking highly effective modulator therapies (HEMTs), particularly elexacaftor/tezacaftor/ivacaftor (ETI), has altered the trajectory toward lung transplant (LTx). PwCF now face greater uncertainty about clinical outcomes and LTx timing.To explore the experiences and perceptions of PwCF regarding LTx in the context of new clinical uncertainty introduced by HEMTs, particularly ETI.This qualitative study was part of a larger trial evaluating an online educational tool ("Take on Transplant"). Participants were adults with CF, FEV1 <50% predicted. qualitative exit interviews were conducted, and data were analyzed using content analysis followed by thematic analysis, achieving data saturation.Among 40 participant interviews, 2 thematic domains emerged. "New Clinical Uncertainty" highlighted ETI's impact, often described as a "game changer" or "miracle," leading to improvements in FEV1, symptoms, and quality of life, delaying LTx discussions for most. Participants commonly engaged in "hedging" about LTx timing, expressing cautious optimism while acknowledging that sudden illness could alter their trajectories. Some experienced "ETI limbo" - being too healthy for LTx yet characterized by anxiety about LTx timing and dissatisfaction with their health and quality of life despite ETI. "Navigating Clinical Uncertainty" identified participants' reliance on FEV1 and other health markers in assessing LTx urgency, high trust in clinicians' knowledge, and appreciation for ongoing clinical conversations about LTx.Clinicians must acknowledge evolving patient perspectives, particularly ETI limbo, and foster ongoing, transparent shared decision-making integrating patient values with clinical data, addressing prognostic uncertainty in this new era of care.
View details for DOI 10.1016/j.hrtlng.2026.102969
View details for PubMedID 42849294
-
Utility of the Telemedicine Retinopathy of Prematurity Severity Score in a Tertiary Neonatal Intensive Care Unit.
Ophthalmic surgery, lasers & imaging retina
2026: 1-6
Abstract
Retinopathy of prematurity (ROP) is a leading cause of childhood blindness. ROP management needs multidisciplinary coordination and clear communication of disease severity. This study aims to evaluate the usability of the Telemedicine ROP Severity Score (tROP-SS) among nonophthalmologists.Twenty-three neonatal intensive care unit (NICU) staff completed a questionnaire with terminology from the International Classification for ROP, Third Edition (ICROP3) or tROP-SS. Participants were assessed on ease of use, identification of progression or regression, and communication with families. Accuracy, number of clicks, and time per question were recorded.Accuracy was higher using tROP-SS terminology vs ICROP3 (76.5% ± 29.2% vs 51.7% ± 20.1%; P = .002). Participants preferred tROP-SS across all subjective domains (P < .001), citing improved understandability, disease assessment, and communication.The tROP-SS enhances both accuracy and usability for NICU staff. By simplifying complex classification into a single score, tROP-SS supports multidisciplinary care.
View details for DOI 10.3928/23258160-20260619-01
View details for PubMedID 42615814
-
Imaging Artifact Mimicking Retinal Detachment in Retinopathy of Prematurity.
Ophthalmic surgery, lasers & imaging retina
2026: 1-2
View details for DOI 10.3928/23258160-20260514-02
View details for PubMedID 42454873
-
Personal narratives to support learning about lung transplant for people with cystic fibrosis.
Patient education and counseling
2025; 137: 108822
Abstract
Cystic fibrosis (CF) causes progressive respiratory disease and premature death. Lung transplantation (LTx) is an important treatment consideration for people with CF (PwCF). Among PwCF, does preparedness for LTx and knowledge about LTx improve by reading personal narratives from CF LTx recipients ("CF Stories")?Adults with CF were recruited and presented with online CF Stories. Pre- and post-intervention questionnaires assessed LTx preparedness, knowledge, and decisional conflict. Deductive thematic analysis of study visits was conducted.Twenty-five participants were included. Pre-intervention, 24 % (6/25) reported feeling "very prepared" to discuss LTx. Among the remaining 19, preparedness improved post-intervention for 74 % (n = 14, 95 % CI: 51-88 %), with 42 % (n = 8, 95 % CI: 23-64 %) transitioning to feeling "very prepared." Baseline transplant knowledge was high (100 % questions correct) among 48 % (12/25) of participants; among the remaining 13, 92 % (n = 12, 95 % CI: 67-99 %) scored 100 % post-intervention. Decisional conflict improved for 67 % of participants (16/24), with a mean individual Decisional Conflict Scale change of -9.4 (95 % CI: -2.8, -15.9; p = 0.01). Thematic analysis revealed that participants valued practical LTx insights and relatable stories, identifying key medical information for LTx discussions.CF Stories improved knowledge and preparedness for LTx discussions.Personal narratives could enhance preparedness for LTx discussions and decision-making for PwCF.
View details for DOI 10.1016/j.pec.2025.108822
View details for PubMedID 40347548
View details for PubMedCentralID PMC12178180
-
Patient perspectives on elexacaftor/tezacaftor/ivacaftor after lung transplant.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
2024; 23 (3): 545-548
Abstract
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators, including elexacaftor/tezacaftor/ivacaftor (ETI), significantly improve outcomes and quality of life for people with cystic fibrosis (CF). However, little is known about how lung transplant recipients (LTRs) perceive the use of ETI. We conducted a survey to assess perspectives on ETI among LTRs with CF at our lung transplant program. Of 81 CF LTRs, 46 participants (58 %) responded. The majority of respondents (88 %) were aware of ETI. Over 80 % considered treating non-lung symptoms of CF to be very important. Concerns regarding ETI included potential drug interactions with transplant medications (77 %), side effects (53 %), cost of medication (49 %), and lack of clinical trial data for LTRs (43 %). Half reported they would only consider taking ETI if their CF or transplant doctor recommended it. The findings suggest that CF LTRs seek informational support and shared decision-making about ETI from their clinicians.
View details for DOI 10.1016/j.jcf.2023.09.017
View details for PubMedID 37798159
View details for PubMedCentralID PMC10987391
-
Multi-level functional genomics reveals molecular and cellular oncogenicity of patient-based 3' untranslated region mutations.
Cell reports
2023; 42 (8): 112840
Abstract
3' untranslated region (3' UTR) somatic mutations represent a largely unexplored avenue of alternative oncogenic gene dysregulation. To determine the significance of 3' UTR mutations in disease, we identify 3' UTR somatic variants across 185 advanced prostate tumors, discovering 14,497 single-nucleotide mutations enriched in oncogenic pathways and 3' UTR regulatory elements. By developing two complementary massively parallel reporter assays, we measure how thousands of patient-based mutations affect mRNA translation and stability and identify hundreds of functional variants that allow us to define determinants of mutation significance. We demonstrate the clinical relevance of these mutations, observing that CRISPR-Cas9 endogenous editing of distinct variants increases cellular stress resistance and that patients harboring oncogenic 3' UTR mutations have a particularly poor prognosis. This work represents an expansive view of the extent to which disease-relevant 3' UTR mutations affect mRNA stability, translation, and cancer progression, uncovering principles of regulatory functionality and potential therapeutic targets in previously unexplored regulatory regions.
View details for DOI 10.1016/j.celrep.2023.112840
View details for PubMedID 37516102
View details for PubMedCentralID PMC10540565